A meta-analysis shows that the blood CX3CL1 levels are not significant different between AD patients and control subjects, yet the large effect size in MCI compared to controls suggests its potential as a biomarker to distinguish MCI patients from healthy individuals (Zhou et al., 2023). Here, CX3CL1 is linked to Alzheimer disease.